基于ResNet-Self-attention架构的阿尔茨海默病阶段预测,贝叶斯优化和最佳特征选择
Nabeela Yaqoob1, Muhammad Attique Khan1, Saleha Masood2
1Department of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
Frontiers in computational neuroscience
|May 10, 2024
概括
这项研究引入了一个使用ResNet-Self和FEcPFA的AI框架,用于准确预测阿尔茨海默病 (AD). 该自动化方法达到99.9%的准确性,有助于早期诊断和减少医疗保健负担.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知和日常功能.
- 早期诊断AD对于患者和家庭的福祉至关重要,但由于缺乏医学专家,面临着挑战.
- 需要自动诊断工具来支持临床医生并提高诊断准确度.
研究的目的:
- 开发一个用于预测阿尔茨海默氏病阶段的自动化框架.
- 通过人工智能 (AI) 和深度学习来提高诊断准确性和效率.
- 为了解决数据集不平衡,并优化特征提取,以改善AD预测.
主要方法:
- 提出了一个新的自动化框架,将ResNet-50与功能提取的自我注意模块集成在一起.
- 采用模糊透控制的路径查找算法 (FEcPFA) 来优化提取的特征.
- 利用贝叶斯优化进行超参数调整和数据增强,以处理数据集不平衡.
主要成果:
- 在使用公共MRI数据集预测阿尔茨海默病阶段时达到99.9%的高准确度.
- 与最先进的 (SOTA) 技术相比,在准确性和时间效率方面表现出卓越的性能.
- 验证了拟议的ResNet-Self架构和FEcPFA在AD诊断中的有效性.
结论:
- 开发的AI框架为阿尔茨海默病诊断提供了高度准确和高效的自动化解决方案.
- 自我注意力机制和FEcPFA的整合显著改善了预测性能.
- 这种方法有可能减轻医疗专业人员的负担,并促进早期发现AD.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
